MeiraGTx announecs five posters at ESGCT 2024 Annual Congress
MeiraGTx (MGTX) announced the Company will exhibit five posters at the European Society of Gene and Cell Therapy, ESGCT, 2024 Annual Congress, ...
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
The posters are available on the Posters and Publications page of the Company’s website.
precisionmedicineonline6d
MeiraGTx to Discuss Parkinson's Gene Therapy Data With Regulators, Planning Phase III Trial
The company said the latest positive safety, tolerability, and efficacy data will underpin discussions with regulators in the US, Europe, and Japan.
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study
MeiraGTx Holdings ’ MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease (PD) met its primary study objective of safety and tolerability. The stock ...
Hosted on MSN6d
MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?
MeiraGTx Holdings PLC (MGTX) shares ended the last trading session 14.9% higher at $5.33. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
MeiraGTx Holdings Reports Promising Parkinson’s Therapy Results
MeiraGTx Holdings has unveiled promising results from its clinical bridging study of AAV-GAD, a gene therapy for Parkinson’s ...